RS
TCRX icon

R Squared’s TScan Therapeutics TCRX Stock Holding History

R Squared’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18K Buy
+18,360
New +$19.6K 0.01% 496
2026
Q1 		– Sell
-16,033
Closed -$16K – 660
2025
Q4 		$16K Sell
16,033
-2,794
-15% -$4.04K 0.01% 500
2025
Q3 		$34.3K Buy
18,827
+7,646
+68% +$13.5K 0.01% 514
2025
Q2 		$16.2K Buy
+11,181
New +$16.2K 0.01% 448

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

R Squared's TCRX Position: Q2 2026 in Review

R Squared opened a new position in TScan Therapeutics (TCRX) in Q2 2026: 18,360 shares worth $18K. The stake represents 0.01% of the portfolio and ranks #496 among its holdings. This is a return to the name: R Squared previously reported a position in TCRX as recently as Q4 2025.

R Squared first reported a position in TCRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $34.3K in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • R Squared held 18,360 shares of TScan Therapeutics worth $18K as of Q2 2026.
  • TScan Therapeutics was a new R Squared position in Q2 2026.
  • TScan Therapeutics made up 0.01% of R Squared's portfolio in Q2 2026, its #496 holding.
  • R Squared first reported a position in TScan Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • R Squared's TScan Therapeutics position peaked at $34.3K in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.